Use of Hormonal Therapy in Men With Metastatic Prostate Cancer

Grace Lu-Yao, Dirk F. Moore, John Oleynick, Robert S. DiPaola, Siu Long Yao

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Purpose: Bilateral orchiectomy or luteinizing hormone releasing hormone agonists represent the standard of care for metastatic prostate cancer. In this population based study we assessed the use rates of these therapies in men who died of prostate cancer. Material and Methods: A total of 9,110 men 65 years or older who died of prostate cancer in 1991 to 2000 were identified through the population based Surveillance, Epidemiology and End Results, and Medicare linked database to determine hormonal therapy use rates. A modified Poisson regression model was used to estimate the adjusted effects of various factors associated with hormone use. Results: Approximately 38% of black and 25% of white men did not receive hormonal therapy before dying of prostate cancer. After adjusting for cancer status at diagnosis and other potential confounding factors black race and residence in low income areas were associated with lower hormonal therapy use (relative risk 0.73, 95% CI 0.67 to 0.80 and 0.91, 95% CI 0.85 to 0.98, respectively). Hormonal therapy use was most comprehensive in the Northeast. Conclusions: A substantial number of men who die as a consequence of prostate cancer never receive hormonal therapy. The use of hormonal therapy varies significantly. Further studies are warranted to determine factors that may be associated with the incomplete use of hormonal therapy for metastatic prostate cancer.

Original languageEnglish (US)
Pages (from-to)526-531
Number of pages6
JournalJournal of Urology
Volume176
Issue number2
DOIs
StatePublished - Aug 2006

All Science Journal Classification (ASJC) codes

  • Urology

Keywords

  • Medicare
  • SEER program
  • antineoplastic agents
  • hormonal
  • prostate
  • prostatic neoplasms

Fingerprint Dive into the research topics of 'Use of Hormonal Therapy in Men With Metastatic Prostate Cancer'. Together they form a unique fingerprint.

Cite this